CPT1A and cancer: The co-up-regulation of CPT1A, SCD and FASN indicated that paclitaxel resistance occurrence is a complicated event which involves multiple metabolic processes, including promoted lipid de novo biosynthesis that meets the need of energy supply and materials required for cancer metastases and invasion.